Developer docs
API playgroundTry for free, no card

Search company profiles

Pandorum Technologies

Full company profile

uuid00027gj

Namestring
Pandorum Technologies
Legal namestring
Pandorum Technologies Pvt. Ltd.
Websiteurl
pandorum.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Pandorum Technologies is a Bengaluru-based clinical-stage biotechnology company founded in 2011 by IISc alumni Tuhin Bhowmick (CEO) and Arun Chandru (CTO) that develops programmable regenerative medicines through a proprietary platform integrating exosome therapeutics, biomaterials, 3D bioprinting, and scalable cellular engineering. The company operates a platform-plus-products model with four pipeline programs: Kuragenx (an exosome-based 'liquid cornea' therapy that received US FDA Orphan Drug Designation for ocular surface diseases including neurotrophic keratitis and Stevens-Johnson Syndrome), Bioengineered Cornea (bioprinted lenticules using proprietary cornea-specific bio-ink for sutureless implantation), Mini Liver (3D human liver organoids used as in vitro disease models), and Lung Regeneration (cell-free exosome therapy for post-COVID-19 pulmonary damage). The platform architecture spans four technology pillars — Bio-Materials with bio-engineered ECM mimics, Cellular Engineering with scalable 2D/3D MSC culture, Exosome & Nanotherapy with MSC-derived regenerative cell modulators, and Bio-Fabrication including 4D bioprinting for hierarchical tissue assembly.

The company's revenue model is pre-commercial across three prospective streams: future therapeutic product sales of Kuragenx and pipeline assets following regulatory approval, drug discovery services using 3D liver organoids sold to pharmaceutical and biotech customers for hepatotoxicity testing and MASH disease modeling, and licensing royalties from platform technology. As of FY24 the company is pre-revenue with reported losses of Rs 28.2 crore, with cumulative funding of approximately $43 million raised across grants, angel, Series A, Pre-Series B CCCPS, and a $18 million Series B in February 2026 led by Protons Corporate at a $91 million post-money valuation. Distribution and manufacturing scale-up are being established through CDMO partnerships with AGC Biologics (US/European supply) and Nucelion Therapeutics, a Bharat Biotech subsidiary (Asia-Pacific supply).

Pandorum serves four identifiable customer segments: ophthalmology hospitals and eye care clinics treating corneal blindness and ocular surface disease, pharmaceutical and biotech companies purchasing 3D liver organoids for drug discovery and DMPK studies, pulmonology practitioners addressing post-COVID-19 ARDS and pulmonary fibrosis, and hepatology specialists for liver tissue engineering and bio-artificial liver applications. The company operates R&D labs in Bangalore (Bangalore BioInnovation Centre and C-CAMP), San Carlos (MBC BioLabs Bay Area), Charleston (Medical University of South Carolina), and Chicago (Northwestern University Feinberg School of Medicine), with stated expansion targets across the US, Japan, and the Middle East.

Short descriptiontext

Pandorum Technologies is a Bengaluru-based clinical-stage biotech developing exosome-based regenerative therapies and 3D bioprinted tissues, with lead program Kuragenx (FDA Orphan Drug Designation for ocular surface diseases), serving ophthalmology, pharmaceutical drug discovery, pulmonology, and hepatology markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBangalore, India
HQ citystring
Bangalore
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
tissue engineering therapeutics, regenerative medicine platform, exosome-based therapies, 3D bioprinting tissues, biomaterials research
Industry3 codes
PRIMARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical Laboratories621511
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
Product category
Regenerative Medicine & Tissue Engineering
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Therapeutic Product Sales
TypeOne Time License
Description

Pre-revenue company developing exosome-based therapies for tissue regeneration. Revenue expected from commercialization of Kuragenx (liquid cornea) and other pipeline products upon regulatory approval.

bwdisrupt.com
2Drug Discovery Services
TypeSubscription Recurring
Description

Mini Liver 3D organoids sold to pharmaceutical and biotech companies for drug metabolism, hepatotoxicity testing, and disease modeling applications.

pandorum.com
3Licensing Royalties
TypeLicensing Royalties
Description

Platform technology may be licensed to larger pharmaceutical partners for specific therapeutic applications or research use.

pandorum.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Kuragenx
Description

Flagship 'liquid cornea' therapy - exosome-based therapeutic for corneal regeneration, treating ocular surface diseases including neurotrophic keratitis and Stevens-Johnson syndrome

pandorum.com
+3 more records
Core offering1 text field

Pandorum Technologies develops programmable regenerative medicine therapies through a proprietary platform combining exosome therapeutics, 3D bioprinting, biomaterials, and cellular engineering. Its core product pipeline includes Kuragenx (an exosome-based liquid cornea therapy), bioengineered corneal tissue products, Mini Liver (3D human liver organoids for drug discovery and disease modeling), and Lung Regeneration (cell-free exosome therapy for post-COVID pulmonary fibrosis). The company also offers drug discovery services using its 3D liver organoid models to pharmaceutical and biotechnology clients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Kuragenx can reverse ulcerative cornea to healthy state in less than a year
+3 more records
Product overview1 text field

Pandorum Technologies is a tissue engineering and regenerative medicine company developing programmable exosome-based therapies through a tunable regenerative platform. The company operates a platform-plus-products model with three core therapeutic pipelines: Kuragenx/Liquid Cornea (bioengineered cornea for vision restoration), Mini Liver (3D liver organoids for drug discovery), and Lung Regeneration (exosome therapy for pulmonary repair). The platform technology combines bio-materials, cellular engineering, exosome & nanotherapy, and bio-fabrication capabilities. The company focuses on disease-modifying, tunable exosome-based therapies targeting tissue health, inflammation, and fibrosis, with expansion beyond ophthalmology to systemic inflammatory and degenerative diseases affecting the lung, liver, and nervous systems.

Product and service4 records
1Kuragenx (Liquid Cornea)
CategoryRegenerative Therapeutics - Ophthalmology
Description

Kuragenx is a bioengineered exosome-based liquid cornea therapy combining specialized exosomes with biopolymeric solution. Applied as eye drops, it solidifies within minutes using visible light and promotes cornea regeneration to restore vision in patients with corneal opacity, ulcers, and neurotrophic keratitis. Targeted at hospitals and eye care clinics treating ocular surface diseases.

2Bioengineered Cornea
CategoryRegenerative Therapeutics - Ophthalmology
Description

Bioengineered corneal tissue products including bioprinted lenticules using proprietary bioinks that mimic native cornea tissue. Designed for sutureless implantation to treat corneal blindness and reduce dependency on donor corneas. Targeted at ophthalmology hospitals and eye care clinics.

3Mini Liver (3D Human Liver Organoids)
CategoryDrug Discovery Services - In Vitro Disease Models
Description

3D human liver tissue models (organoids) used for drug discovery, hepatotoxicity testing, DMPK studies, and disease modeling including NASH/MASH, steatosis, and fibrosis. Mimics in vivo disease physiology for accurate drug effect prediction. Sold to pharmaceutical and biotechnology companies for preclinical research and therapeutic development applications.

4Lung Regeneration (Exosome Therapy)
CategoryRegenerative Therapeutics - Pulmonology
Description

Cell-free exosome-based therapy for post-COVID-19 lung trauma and pulmonary fibrosis. Uses immunomodulatory and anti-fibrotic exosomal factors to repair lung tissue damage from inflammation and fibrosis. Targeted at hospitals and pulmonology clinics treating post-viral lung damage and inflammatory lung conditions.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeTechnology or Integration
Description

CDMO partnership with AGC Biologics in Italy for manufacturing and supply of exosome-based therapies in US and European markets. Supports global manufacturing scale-up for Kuragenx and other pipeline products.

Strategic tierCoreTypeTechnology or Integration
Description

Partnership with Nucelion Therapeutics, a wholly owned subsidiary of Bharat Biotech, for end-to-end manufacturing including process scale-up, GMP-compliant production, and quality control of pharmaceutical-grade exosomes derived from clinical-grade mesenchymal stem cells. Covers Asia-Pacific distribution.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Established research and operational hub within Northwestern University facilities. Clinical partner for First in Human clinical study for Kuragenx (Liquid Cornea). Uses advanced label-free live cell imaging technologies (Holomonitor, NanoLive) for exosome characterization. Expertise in corneal stromal stem cells and ex vivo analyses.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with MUSC Translational Research and Immunobiology Institute (TRII) for accelerated clinical translation in US. SAMPSON 1 study for COVID-19 induced ARDS using UCMSC therapy. Dr. Satish Nadig serves as Chief Medical Advisor. MUSC provides FDA registered cGMP facility for cell therapy.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical collaboration for corneal translational research in India. Dr. Virender Sangwan guides the corneal project. Key site for Kuragenx clinical trials in India.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Swiss 3D organoid and organ-on-chip company offering liver, pancreatic, and tumor models for pharma drug discovery. Closely comparable service-line peer to Pandorum Mini Liver's pharma offering.

TypeDirect peer
Description

Clinical-stage biotech developing exosome-based therapeutics (CAP-1002, CAP-2003) for cardiac and inflammatory indications. Most directly comparable to Pandorum in using MSC-derived extracellular vesicles/exosomes as a regenerative modality, with clinical-stage assets.

TypeDirect peer
Description

Commercial/clinical-stage cell therapy company using mesenchymal lineage cells for inflammatory and cardiovascular diseases. Comparable to Pandorum in MSC-derived regenerative platform with multiple clinical assets and global ambitions.

TypeBroad incumbent
Description

Commercial-stage regenerative medicine company selling bioengineered skin and wound healing products (Apligraf, Dermagraft). A relevant incumbent peer for Pandorum's bioengineered cornea and tissue regeneration ambitions, illustrating the commercial pathway and reimbursement challenges.

TypeDirect peer
Description

Global leader in bioprinting technology, bioinks, and lab automation for life sciences. Directly comparable to Pandorum on the 4D bioprinting and bio-ink technology platform; CellInk is already a Pandorum technology partner.

TypeDirect peer
Description

Pioneer in 3D bioprinting of human tissues for therapeutic and research applications, including liver tissue. Direct peer on the 3D-printed functional tissue technology axis, particularly comparable to Pandorum's Mini Liver program.

TypeEmerging player
Description

Commercial-stage organ-on-chip and in vitro liver models for drug discovery. Comparable to Pandorum's Mini Liver organoid drug discovery service business; both target pharma DMPK and hepatotoxicity testing.

TypeDirect peer
Description

Clinical-stage cell therapy and regenerative medicine company using placental-derived cells and exosomes. Comparable to Pandorum on MSC/exosome-based regenerative therapeutics and the goal of cell-free exosome products.

9Athersys
TypeEmerging player
Description

Clinical-stage regenerative medicine company developing MultiStem cell therapy for stroke, ARDS, and inflammatory conditions. Comparable to Pandorum on cell-based therapy for pulmonary/post-inflammatory regeneration (ARDS/pulmonary fibrosis indication overlap).

10Aspect Biosystems
TypeEmerging player
Description

Canadian 3D bioprinting company developing tissue therapeutics (with partners including Novo Nordisk). Comparable to Pandorum on bioprinted tissue therapeutics platform, though focused on metabolic disease and pancreatic tissue.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pandorum Technologies

Regenerative Medicine & Tissue Engineeringpandorum.com

Pandorum Technologies is a Bengaluru-based clinical-stage biotech developing exosome-based regenerative therapies and 3D bioprinted tissues, with lead program Kuragenx (FDA Orphan Drug Designation for ocular surface diseases), serving ophthalmology, pharmaceutical drug discovery, pulmonology, and hepatology markets.

What Pandorum Technologies does

Pandorum Technologies is a Bengaluru-based clinical-stage biotechnology company founded in 2011 by IISc alumni Tuhin Bhowmick (CEO) and Arun Chandru (CTO) that develops programmable regenerative medicines through a proprietary platform integrating exosome therapeutics, biomaterials, 3D bioprinting, and scalable cellular engineering. The company operates a platform-plus-products model with four pipeline programs: Kuragenx (an exosome-based 'liquid cornea' therapy that received US FDA Orphan Drug Designation for ocular surface diseases including neurotrophic keratitis and Stevens-Johnson Syndrome), Bioengineered Cornea (bioprinted lenticules using proprietary cornea-specific bio-ink for sutureless implantation), Mini Liver (3D human liver organoids used as in vitro disease models), and Lung Regeneration (cell-free exosome therapy for post-COVID-19 pulmonary damage). The platform architecture spans four technology pillars — Bio-Materials with bio-engineered ECM mimics, Cellular Engineering with scalable 2D/3D MSC culture, Exosome & Nanotherapy with MSC-derived regenerative cell modulators, and Bio-Fabrication including 4D bioprinting for hierarchical tissue assembly.

The company's revenue model is pre-commercial across three prospective streams: future therapeutic product sales of Kuragenx and pipeline assets following regulatory approval, drug discovery services using 3D liver organoids sold to pharmaceutical and biotech customers for hepatotoxicity testing and MASH disease modeling, and licensing royalties from platform technology. As of FY24 the company is pre-revenue with reported losses of Rs 28.2 crore, with cumulative funding of approximately $43 million raised across grants, angel, Series A, Pre-Series B CCCPS, and a $18 million Series B in February 2026 led by Protons Corporate at a $91 million post-money valuation. Distribution and manufacturing scale-up are being established through CDMO partnerships with AGC Biologics (US/European supply) and Nucelion Therapeutics, a Bharat Biotech subsidiary (Asia-Pacific supply).

Pandorum serves four identifiable customer segments: ophthalmology hospitals and eye care clinics treating corneal blindness and ocular surface disease, pharmaceutical and biotech companies purchasing 3D liver organoids for drug discovery and DMPK studies, pulmonology practitioners addressing post-COVID-19 ARDS and pulmonary fibrosis, and hepatology specialists for liver tissue engineering and bio-artificial liver applications. The company operates R&D labs in Bangalore (Bangalore BioInnovation Centre and C-CAMP), San Carlos (MBC BioLabs Bay Area), Charleston (Medical University of South Carolina), and Chicago (Northwestern University Feinberg School of Medicine), with stated expansion targets across the US, Japan, and the Middle East.

Pandorum Technologies firmographics

Firmographics
Name
Pandorum Technologies
Legal name
Pandorum Technologies Pvt. Ltd.
Website
https://pandorum.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Short description
Pandorum Technologies is a Bengaluru-based clinical-stage biotech developing exosome-based regenerative therapies and 3D bioprinted tissues, with lead program Kuragenx (FDA Orphan Drug Designation for ocular surface diseases), serving ophthalmology, pharmaceutical drug discovery, pulmonology, and hepatology markets.
Ownership category
akta.pro rank

Pandorum Technologies industry classification

Industry
Product category
Regenerative Medicine & Tissue Engineering
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Tissue engineering therapeutics
  • Regenerative medicine platform
  • Exosome-based therapies
  • 3D bioprinting tissues
  • Biomaterials research

Where Pandorum Technologies is headquartered

Location

Headquarters

HQ city
Bangalore
HQ country
India
HQ region
Asia

Offices4 records

Markets served

Pandorum Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Therapeutic Product Sales: Pre-revenue company developing exosome-based therapies for tissue regeneration. Revenue expected from commercialization of Kuragenx (liquid cornea) and other pipeline products upon regulatory approval.
  2. Drug Discovery Services: Mini Liver 3D organoids sold to pharmaceutical and biotech companies for drug metabolism, hepatotoxicity testing, and disease modeling applications.
  3. Licensing Royalties: Platform technology may be licensed to larger pharmaceutical partners for specific therapeutic applications or research use.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Pandorum Technologies product offering

Product offering

Core offering

Pandorum Technologies develops programmable regenerative medicine therapies through a proprietary platform combining exosome therapeutics, 3D bioprinting, biomaterials, and cellular engineering. Its core product pipeline includes Kuragenx (an exosome-based liquid cornea therapy), bioengineered corneal tissue products, Mini Liver (3D human liver organoids for drug discovery and disease modeling), and Lung Regeneration (cell-free exosome therapy for post-COVID pulmonary fibrosis). The company also offers drug discovery services using its 3D liver organoid models to pharmaceutical and biotechnology clients.

Product overview

Pandorum Technologies is a tissue engineering and regenerative medicine company developing programmable exosome-based therapies through a tunable regenerative platform. The company operates a platform-plus-products model with three core therapeutic pipelines: Kuragenx/Liquid Cornea (bioengineered cornea for vision restoration), Mini Liver (3D liver organoids for drug discovery), and Lung Regeneration (exosome therapy for pulmonary repair). The platform technology combines bio-materials, cellular engineering, exosome & nanotherapy, and bio-fabrication capabilities. The company focuses on disease-modifying, tunable exosome-based therapies targeting tissue health, inflammation, and fibrosis, with expansion beyond ophthalmology to systemic inflammatory and degenerative diseases affecting the lung, liver, and nervous systems.

Differentiator

Problem solved

Functional benefit

Brands

  • Kuragenx: Flagship 'liquid cornea' therapy - exosome-based therapeutic for corneal regeneration, treating ocular surface diseases including neurotrophic keratitis and Stevens-Johnson syndrome
  • Bioengineered Cornea
  • Mini Liver
  • Lung Regeneration

Products and services

  • Kuragenx (Liquid Cornea) Kuragenx is a bioengineered exosome-based liquid cornea therapy combining specialized exosomes with biopolymeric solution. Applied as eye drops, it solidifies within minutes using visible light and promotes cornea regeneration to restore vision in patients with corneal opacity, ulcers, and neurotrophic keratitis. Targeted at hospitals and eye care clinics treating ocular surface diseases.
  • Bioengineered Cornea Bioengineered corneal tissue products including bioprinted lenticules using proprietary bioinks that mimic native cornea tissue. Designed for sutureless implantation to treat corneal blindness and reduce dependency on donor corneas. Targeted at ophthalmology hospitals and eye care clinics.
  • Mini Liver (3D Human Liver Organoids) 3D human liver tissue models (organoids) used for drug discovery, hepatotoxicity testing, DMPK studies, and disease modeling including NASH/MASH, steatosis, and fibrosis. Mimics in vivo disease physiology for accurate drug effect prediction. Sold to pharmaceutical and biotechnology companies for preclinical research and therapeutic development applications.
  • Lung Regeneration (Exosome Therapy) Cell-free exosome-based therapy for post-COVID-19 lung trauma and pulmonary fibrosis. Uses immunomodulatory and anti-fibrotic exosomal factors to repair lung tissue damage from inflammation and fibrosis. Targeted at hospitals and pulmonology clinics treating post-viral lung damage and inflammatory lung conditions.

Quantifiable outcome

  • Kuragenx can reverse ulcerative cornea to healthy state in less than a year
  • +3 more outcomes

Companies that use Pandorum Technologies

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Pandorum Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Pandorum Technologies partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • AGC BiologicscoreTechnology or IntegrationCDMO partnership with AGC Biologics in Italy for manufacturing and supply of exosome-based therapies in US and European markets. Supports global manufacturing scale-up for Kuragenx and other pipeline products.
  • Nucelion Therapeutics (Bharat Biotech)coreTechnology or IntegrationPartnership with Nucelion Therapeutics, a wholly owned subsidiary of Bharat Biotech, for end-to-end manufacturing including process scale-up, GMP-compliant production, and quality control of pharmaceutical-grade exosomes derived from clinical-grade mesenchymal stem cells. Covers Asia-Pacific distribution.
  • Northwestern UniversitycoreStrategic or Co-development PartnerEstablished research and operational hub within Northwestern University facilities. Clinical partner for First in Human clinical study for Kuragenx (Liquid Cornea). Uses advanced label-free live cell imaging technologies (Holomonitor, NanoLive) for exosome characterization. Expertise in corneal stromal stem cells and ex vivo analyses.
  • Medical University of South Carolina (MUSC)coreStrategic or Co-development PartnerCollaboration with MUSC Translational Research and Immunobiology Institute (TRII) for accelerated clinical translation in US. SAMPSON 1 study for COVID-19 induced ARDS using UCMSC therapy. Dr. Satish Nadig serves as Chief Medical Advisor. MUSC provides FDA registered cGMP facility for cell therapy.
  • Dr. Shroff's Charity Eye HospitalcoreStrategic or Co-development PartnerClinical collaboration for corneal translational research in India. Dr. Virender Sangwan guides the corneal project. Key site for Kuragenx clinical trials in India.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Pandorum Technologies competitors and assessment

Company assessment

Emerging players

  • InSphero: Swiss 3D organoid and organ-on-chip company offering liver, pancreatic, and tumor models for pharma drug discovery. Closely comparable service-line peer to Pandorum Mini Liver's pharma offering.
  • Emulate Inc. Commercial-stage organ-on-chip and in vitro liver models for drug discovery. Comparable to Pandorum's Mini Liver organoid drug discovery service business; both target pharma DMPK and hepatotoxicity testing.
  • Athersys: Clinical-stage regenerative medicine company developing MultiStem cell therapy for stroke, ARDS, and inflammatory conditions. Comparable to Pandorum on cell-based therapy for pulmonary/post-inflammatory regeneration (ARDS/pulmonary fibrosis indication overlap).
  • Aspect Biosystems: Canadian 3D bioprinting company developing tissue therapeutics (with partners including Novo Nordisk). Comparable to Pandorum on bioprinted tissue therapeutics platform, though focused on metabolic disease and pancreatic tissue.

Direct peers

  • Capricor Therapeutics: Clinical-stage biotech developing exosome-based therapeutics (CAP-1002, CAP-2003) for cardiac and inflammatory indications. Most directly comparable to Pandorum in using MSC-derived extracellular vesicles/exosomes as a regenerative modality, with clinical-stage assets.
  • Mesoblast: Commercial/clinical-stage cell therapy company using mesenchymal lineage cells for inflammatory and cardiovascular diseases. Comparable to Pandorum in MSC-derived regenerative platform with multiple clinical assets and global ambitions.
  • Cellink (BICO Group): Global leader in bioprinting technology, bioinks, and lab automation for life sciences. Directly comparable to Pandorum on the 4D bioprinting and bio-ink technology platform; CellInk is already a Pandorum technology partner.
  • Organovo: Pioneer in 3D bioprinting of human tissues for therapeutic and research applications, including liver tissue. Direct peer on the 3D-printed functional tissue technology axis, particularly comparable to Pandorum's Mini Liver program.
  • Celularity Inc. Clinical-stage cell therapy and regenerative medicine company using placental-derived cells and exosomes. Comparable to Pandorum on MSC/exosome-based regenerative therapeutics and the goal of cell-free exosome products.

Broad incumbents

  • Organogenesis Holdings: Commercial-stage regenerative medicine company selling bioengineered skin and wound healing products (Apligraf, Dermagraft). A relevant incumbent peer for Pandorum's bioengineered cornea and tissue regeneration ambitions, illustrating the commercial pathway and reimbursement challenges.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Pandorum Technologies social profiles

Digital presence

Pandorum Technologies compliance and trust

Trust signal

Compliance1 record

Pandorum Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pandorum Technologies leadership team

Management profile

Number of profiles

Profiles8 records

Pandorum Technologies subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Pandorum Technologies funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pandorum Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pandorum Technologies

What does Pandorum Technologies do?

Pandorum Technologies develops programmable regenerative medicine therapies through a proprietary platform combining exosome therapeutics, 3D bioprinting, biomaterials, and cellular engineering. Its core product pipeline includes Kuragenx (an exosome-based liquid cornea therapy), bioengineered corneal tissue products, Mini Liver (3D human liver organoids for drug discovery and disease modeling), and Lung Regeneration (cell-free exosome therapy for post-COVID pulmonary fibrosis). The company also offers drug discovery services using its 3D liver organoid models to pharmaceutical and biotechnology clients.

Is Pandorum Technologies a public or private company?

Pandorum Technologies is a private company. It is classified as venture growth investor backed and is currently operating.

When was Pandorum Technologies founded?

Pandorum Technologies was founded in 2011. It employs 11 to 50 people.

Where is Pandorum Technologies based?

Pandorum Technologies is headquartered in Bangalore, India, in the Asia region.

How does Pandorum Technologies make money?

Three revenue lines are on record. Therapeutic Product Sales are the primary driver. The others are drug Discovery Services and licensing Royalties.

Who are Pandorum Technologies's main competitors?

Emerging players on record are InSphero, Emulate Inc., Athersys and Aspect Biosystems. Direct peers are Capricor Therapeutics, Mesoblast, Cellink (BICO Group), Organovo and Celularity Inc.. Organogenesis Holdings is listed as a broad incumbent.

Does Pandorum Technologies have an API?

No public API is recorded for Pandorum Technologies.

What industry is Pandorum Technologies in?

Pandorum Technologies's product category is Regenerative Medicine & Tissue Engineering. Its primary akta.pro industry code is HLAAAGAD, Organoids & Organ-on-Chip (regenerative models), with a secondary code of HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The HinduBharat Biotech arm Nucelion to collaborate with Pandorum Tech on two PRIP-backed projectsNucelion Therapeutics and Pandorum Technologies will collaborate on two ophthalmology projects under the PRIP scheme, focusing on keratopathy and wet AMD. The combined outlay is ₹16.97 crore, including up to ₹8 crore in PRIP funding. The partnership aims to provide GMP-manufactured materials for clinical studies in India and abroad.The Times of IndiaBharat Biotech’s Nucelion, Pandorum in manufacturing partnership for eye disease therapies | Hyderabad News - The Times of IndiaNucelion Therapeutics, a Bharat Biotech subsidiary, partnered with Pandorum Technologies to advance two ophthalmology programmes using designer exosomes for keratopathy and wet age-related macular degeneration. The projects have a combined planned outlay of ₹16.97 crore, including up to ₹8 crore in PRIP funding, with manufacturing under Good Manufacturing Practices for clinical studies.Fortune IndiaBharat Biotech arm Nucelion inks manufacturing pact with Pandorum to develop ophthalmology therapiesNucelion Therapeutics and Pandorum Technologies announced a partnership to develop investigational therapies for advanced keratopathy and wet age-related macular degeneration. The projects have a combined planned outlay of ₹16.97 crore, including up to ₹8 crore under the central government's PRIP scheme. The collaboration aims to produce GMP-manufactured biologics for clinical studies in India and abroad.Fortune IndiaBharat Biotech arm Nucelion inks manufacturing pact with Pandorum to develop ophthalmology therapiesNucelion Therapeutics and Pandorum Technologies announced a partnership to develop investigational therapies for advanced keratopathy and wet age-related macular degeneration. The projects have a combined planned outlay of ₹16.97 crore, including up to ₹8 crore under the PRIP scheme. The collaboration aims to build GMP manufacturing capabilities in India for clinical studies.WhalesbookNucelion, Pandorum Partner for ₹17 Cr Eye Drug ResearchNucelion Therapeutics and Pandorum Technologies launched a ₹17 crore project to develop gene therapy for advanced keratopathy and wet AMD. The government's PRIP scheme provides ₹8 crore in funding. The collaboration aims to bridge research and clinical trials using designer exosomes.BusinessLineNucelion Therapeutics, Pandorum Technologies to take up 2 ophthalmology projectsNucelion Therapeutics and Pandorum Technologies will develop investigational therapies for advanced keratopathy and wet AMD. The projects have a combined planned outlay of about ₹17 crore, including up to ₹8 crore under the PRIP scheme. The collaboration aims to provide GMP-manufactured materials for clinical studies in India and abroad.BioSpaceIndia’s life sciences sector at turning point for innovation: ReportA joint report by Boston Consulting Group and HealthKois finds that India's life sciences sector has made significant innovation progress over the past decade, with patent filings increasing more than fourfold since 2016 and private capital for healthcare innovation rising sharply to $731 million in fiscal year 2026. The report identifies structural gaps hindering scalability, including insufficient public funding, low venture capital risk appetite for biotech, and clinical trial approval times of around 90 days compared to 30 days in the United States. Notable milestones highlighted include Wockhardt's FDA approval for its antibiotic Zaynich and Pandorum Technologies raising $18 million in Series B funding to advance exosome-based therapies.TechBullion5 HealthTech Startups Developing Hepatology SolutionsThis article profiles five healthtech startups developing solutions for liver disease, a condition affecting hundreds of millions globally that often goes undiagnosed until advanced stages. The companies profiled—Akero Therapeutics, Madrigal Pharmaceuticals, Alentis Therapeutics, Enyo Pharma, and Pandorum Technologies—each take distinct approaches including drug development for MASH and Hepatitis B, antibody therapies for fibrosis and liver cancer, and bioengineered liver tissue. Madrigal Pharmaceuticals achieved a landmark in 2024 when the FDA approved Rezdiffra as the first treatment for MASH with liver fibrosis, while collectively these companies have raised over $1.4 billion, signaling significant investor interest in the hepatology space.VentureRadarNew Funding Rounds in "industrial iot"Multiple venture-funded companies in the industrial IoT sector received funding, including Treon, Emproof, Datoms, CraftifAI, Satlabs Space Systems, Pandorum Technologies, Sensesemi, Tulip Interfaces, BrainChip, INLAN, Inc., and Procense. The funding rounds ranged from seed to Series D and supported technologies in AI, sensor security, satellite connectivity, tissue engineering, and supply chain management.Mpo-magPandorum Technologies Raises $18 Million in Series B FundingPandorum Technologies has closed an $18 million Series B financing round led by Protons Corporate, with participation from Galentic Pharma, investor Ashish Kacholia, Noblevast Advisory Avinya Fund, Burman family, and others, to advance its exosome-based therapies including Kuragenx. The funding will support clinical development, scale global manufacturing across the United States, Japan, and the Middle East, and expand operations, with Kuragenx having already received FDA Orphan Drug Designation for ocular surface diseases. The company operates research facilities in India and maintains manufacturing partnerships with AGC Biologics for U.S. and European markets and Nucelion Therapeutics for Asia-Pacific supply.